Floatz logo

Cynk-001

Hemostatic Disorder

Celularity IncorporatedCell therapyPhase 1Dormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Hemostatic Disorder cohort.

Asset / SponsorPhaseRating
Oricar-017
OriCell Therapeutics Co., Ltd.
Phase 1CC
Kln-1010
Kelonia Therapeutics, Inc.
Phase 1CC
HUMAN ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX
Assiut University
D
Tranexamic Acid
Assiut University
D

Same molecule, other indications

Cynk-001 is also rated in:

giant cell glioblastomaDormant
C
Indicative ·
37 / 100
View asset →
glioblastomaDormant
C
Indicative ·
37 / 100
View asset →
monoclonal paraproteinemia diseaseDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →